Skip to main content
SpringerLink
Log in

Pentraxin-3 concentrations in stable coronary artery disease depend on the clinical presentation

  • Research Article
  • Published:
European Cytokine Network Aims and scope

Abstract

Introduction

Pentraxin-3 (PTX3) is an acute-phase reactant that shares structural and functional homology with C-reactive protein (CRP). However, unlike CRP, which is synthesized mainly in the liver, PTX3 is produced at the site of inflammation. It has been suggested that PTX3 plays the same role in the periphery that CRP does in circulation. PTX3 may represent a rapid marker of local inflammation.

Methods

Fifty-one patients with stable coronary artery disease (CAD) were enrolled. Blood samples were collected on admission. Plasma concentration of PTX3 and high-sensitivity CRP (hsCRP) were determined.

Results

Median PTX3 concentration was 0.92 μmol/L (0.58–1.40). Median hsCRP concentration was 0.90 mg/L (0.75–1.10). There was a positive correlation between PTX3 and total cholesterol (R = 0.34; P = 0.01), PTX3 and LDL cholesterol (R = 0.35; P = 0.01), and PTX3 and hsCRP (R = 0.46; P = 0.0005). We found no correlation between hsCRP and all laboratory parameters. We found higher PTX3 concentrations in patients with Canadian Cardiovascular Society (CCS) functional class 3 (compared to CCS functional class 2) and in patients taking nitrates. Lower PTX3 concentrations were reported in patients taking calcium channel blockers (amlodipine). hsCRP concentrations remained similar among these subgroups of patients.

Conclusions

PTX3 is a marker of clinically more advanced CAD (CCS2 vs CCS3; nitrates vs no nitrates). PTX3 is also associated with other cardiovascular risk factors (total cholesterol, LDL cholesterol, and hsCRP). PTX3 may be a potential early marker of cardiovascular risk before the increase of systemic markers like hsCRP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Drakopoulou M, Toutouzas K, Michelongona A, Tousoulis D, Stefanadis C. Vulnerable plaque and inflammation: potential clinical strategies. Curr Pharm Des 2011; 17: 4190.

    Article  CAS  PubMed  Google Scholar 

  2. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32: 2045.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 2004; 116(Suppl 6A): 9S.

    Article  Google Scholar 

  4. Nakou ES, Liberopoulos EN, Milionis HJ, Elisaf MS. The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview. Curr Vasc Pharmacol 2008; 6: 258.

    Article  CAS  PubMed  Google Scholar 

  5. Mantovani A, Garlanda C, Bottazzi B, et al. The long pentraxinPTX3 in vascular pathology. Vascul Pharmacol 2006; 45: 326.

    Article  CAS  PubMed  Google Scholar 

  6. Abderrahim-Ferkoune A, Bezy O, Chiellini C, et al. Characterization of the long pentraxin PTX3 as a TNFalpha-induced secreted protein of adipose cells. J Lipid Res 2003; 44: 994.

    Article  CAS  PubMed  Google Scholar 

  7. Norata GD, Garlanda C, Catapano AL. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med 2010; 20: 35.

    Article  CAS  PubMed  Google Scholar 

  8. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005; 23: 337.

    Article  CAS  PubMed  Google Scholar 

  9. Soeki T, Niki T, Kusunose K, et al. Elevated concentrations of pentraxin 3 are associated with coronary plaque vulnerability. J Cardiol 2011; 58: 151.

    Article  PubMed  Google Scholar 

  10. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002; 22: e10.

    Article  Google Scholar 

  11. Savchenko A, Imamura M, Ohashi R, et al. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 2008; 215: 48.

    Article  CAS  PubMed  Google Scholar 

  12. Knoflach M, Kiechl S, Kind M, et al. Cardiovascular risk factors and atherosclerosis in young males: ARMY study (Atherosclerosis Risk-Factors in Male Youngsters). Circulation 2003; 108: 1064.

    Article  PubMed  Google Scholar 

  13. Knoflach M, Kiechl S, Penz D, et al. Cardiovascular risk factors and atherosclerosis in young women: atherosclerosis risk factors in female youngsters (ARFY study). Stroke 2009; 40: 1063.

    Article  CAS  PubMed  Google Scholar 

  14. Peri G, Introna M, Corradi D, et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000; 102: 636.

    Article  CAS  PubMed  Google Scholar 

  15. Inoue K, Sugiyama A, Reid PC, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007; 27: 161.

    Article  CAS  PubMed  Google Scholar 

  16. Haybar H, Assareh A, Ghotbi Y, Torabizadeh M, Bozorgmanesh M. Incremental diagnostic value of circulating pentraxin in patients with intermediate risk of coronary artery disease. Heart 2013; 99: 640.

    Article  PubMed  Google Scholar 

  17. Dubin R, Li Y, Ix JH, Shlipak MG, Whooley M, Peralta CA. Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study. Am Heart J 2012; 163: 274.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Kotooka N, Inoue T, Aoki S, Anan M, Komoda H, Node K. Prognostic value of pentraxin 3 in patients with chronic heart failure. Int J Cardiol 2008; 130: 19.

    Article  PubMed  Google Scholar 

  19. Kotooka N, Inoue T, Fujimatsu D, et al. Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening. Atherosclerosis 2008; 197: 368.

    Article  CAS  PubMed  Google Scholar 

  20. Hudzik B, Szkodzinski J, Pietka-Rzycka A, et al. Plasma pentraxin 3 may be a more sensitive marker of inflammatory response than high-sensitivity C-reactive protein after bare-metal stent compared to drug-eluting stent implantation. J Interferon Cytokine Res 2013; 33: 280.

    Article  CAS  PubMed  Google Scholar 

  21. Knoflach M, Kiechl S, Mantovani A, et al. Pentraxin-3 as a marker of advanced atherosclerosis results from the Bruneck, ARMY and ARFY Studies. PLoS One 2012; 7: e31474.

    Article  Google Scholar 

  22. Matsui S, Ishii J, Kitagawa F, et al. Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis 2010; 210: 220.

    Article  CAS  PubMed  Google Scholar 

  23. Norata GD, Marchesi P, Pulakazhi Venu VK, et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 2009; 120: 699.

    Article  CAS  PubMed  Google Scholar 

  24. Norata GD, Marchesi P, Pirillo A, et al. Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol 2008; 28: 925.

    Article  CAS  PubMed  Google Scholar 

  25. Salio M, Chimenti S, De Angelis N, et al. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2008; 117: 1055.

    Article  CAS  PubMed  Google Scholar 

  26. Doni A, Michela M, Bottazzi B, et al. Regulation of PTX3, a key component of humoral innate immunity in human dendritic cells: stimulation by IL-10 and inhibition by IFN-gamma. J Leukoc Biol 2006; 79: 797.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Third Department of Cardiology, Silesian Center for Heart Disease, Medical University of Silesia, Curie-Sklodowska 9, 41-800, Zabrze, Poland

    Bartosz Hudzik, Janusz Szkodzinski & Lech Polonski

  2. Department of Nutrition-Associated Disease Prevention, Faculty of Public Health, Medical University of Silesia, Bytom, Poland

    Aleksander Danikiewicz & Barbara Zubelewicz-Szkodzinska

  3. Division of Endocrinology, County Hospital, Piekary Slaskie, Poland

    Barbara Zubelewicz-Szkodzinska

Authors
  1. Bartosz Hudzik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aleksander Danikiewicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Janusz Szkodzinski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lech Polonski
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Barbara Zubelewicz-Szkodzinska
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bartosz Hudzik.

Additional information

Equal contribution to the paper.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hudzik, B., Danikiewicz, A., Szkodzinski, J. et al. Pentraxin-3 concentrations in stable coronary artery disease depend on the clinical presentation. Eur Cytokine Netw 25, 41–45 (2014). https://doi.org/10.1684/ecn.2014.0354

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ecn.2014.0354

Key words

Search

Navigation